These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27170206)

  • 1. I am the 9%: Making the case for whole-blood platelets.
    Seheult JN; Triulzi DJ; Yazer MH
    Transfus Med; 2016 Jun; 26(3):177-85. PubMed ID: 27170206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML; Rivera J; Vicente V
    Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.
    Bell CE; Botteman MF; Gao X; Weissfeld JL; Postma MJ; Pashos CL; Triulzi D; Staginnus U
    Clin Ther; 2003 Sep; 25(9):2464-86. PubMed ID: 14604745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical comparison of platelet preparation methods.
    Vassallo RR; Murphy S
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
    Thiele T; Alt-Mayer T; Greinacher A; Bux J
    Vox Sang; 2016 Nov; 111(4):350-356. PubMed ID: 27432635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets.
    Schrezenmeier H; Walther-Wenke G; Müller TH; Weinauer F; Younis A; Holland-Letz T; Geis G; Asmus J; Bauerfeind U; Burkhart J; Deitenbeck R; Förstemann E; Gebauer W; Höchsmann B; Karakassopoulos A; Liebscher UM; Sänger W; Schmidt M; Schunter F; Sireis W; Seifried E
    Transfusion; 2007 Apr; 47(4):644-52. PubMed ID: 17381623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bacterial contamination: should it be detected or inactivated?].
    Cazenave JP
    Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
    van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
    Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components.
    Xiao W; Tormey CA; Capetillo A; Maitta RW
    Vox Sang; 2013 Nov; 105(4):334-40. PubMed ID: 23802769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of PEG-rhuMGDF in platelet apheresis.
    Kuter DJ
    Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.
    Hillyer CD; Josephson CD; Blajchman MA; Vostal JG; Epstein JS; Goodman JL
    Hematology Am Soc Hematol Educ Program; 2003; ():575-89. PubMed ID: 14633800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red blood cell alloimmunisation after platelet transfusion (excluding ABO blood group system).
    Moncharmont P
    Transfus Clin Biol; 2020 Aug; 27(3):185-190. PubMed ID: 32544526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients.
    Klausen SS; Hervig T; Seghatchian J; Reikvam H
    Transfus Apher Sci; 2014 Oct; 51(2):97-102. PubMed ID: 25242310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.